Council for Responsible Nutrition Supplyside West, October 19, 2006 The Case for Mandatory Reporting of Adverse Events for Dietary Supplements Steve Mister.

Slides:



Advertisements
Similar presentations
Susan Burner Bankowski, M.S., J.D. Chair, OHSU IRB
Advertisements

2402 W. Jefferson Street, Boise, ID Tel: Advance Directives: Proactive Planning That Benefits You And Your Family.
TM The HIPAA Privacy Rule: Safeguarding Health Information in Research and Public Health Practice Centers for Disease Control and Prevention Beverly A.
Clinical Trials: Clinical Research Billing, MSP, MMSEA, and Other Issues Meant to Complicate Our Lives 2011 Corporate Council Meeting 17 February 2011.
ALERT: The Basics Food and Drug Administration Center for Food Safety and Applied Nutrition.
Reporting Unanticipated Problems Involving Risk to Subjects or Others and Adverse Events WFUHS Policy/Procedure Effective Date 6/1/07 Wendy Murray Monitoring.
Comm2315.wordpress.com.  On the Record – All statements are subject for use in the story. Everything a source says or s you is.
UNITED SPINAL ASSOCIATION AUGUST, 2014 Biologics & Biosimilars: An Overview 1.
Update: 21 CFR PART 312 FDA Safety Reporting Requirements for INDs
OUT IN FRONT OSHA Update: A Discussion About Two New Game-Changing Rule Changes Effective January 1, 2015 And a “Stealth Rule” expected to be effective.
How to Conduct Accident Investigations Getting to the bottom line of loss prevention!
1.  Incident reports should be written only when you are sure that a persons rights have been violated. True False  Full names of consumers should never.
A Guide for Estheticians Liability and Risk Reduction Associated Skin Care Professionals
Field Investigators: ADE Detectives. Section One Introduction to the Team and Their Roles.
 2011 Johns Hopkins Bloomberg School of Public Health Regulation of Tobacco Products Mitch Zeller, JD Pinney Associates.
FDA’s MedWatch Program Outreach to Healthcare Professionals and the Public n Managing the Risks of Medical Product Use.
Consumer Protection Agencies Introduction to Business & Marketing.
FDA MedWatch and Patient Safety. Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006  The Act defines a ‘serious adverse event’
Chapter 18.  Criminal Law: crime against the state  Civil Law: person commits a wrong, not always a violation of law  Plaintiff-the harmed individual,
Probiotics: Safety Issues Francis B Palumbo, PhD, Esq. University of Maryland School of Pharmacy Center on Drugs & Public Policy.
Dietary Supplements Bradford W. Williams Special Assistant Division of Dietary Supplement Programs ONPLDS, CFSAN, FDA.
What You Want to Know About Generic Drugs Generic Drugs: Safe. Effective. FDA-Approved.
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
POSTMARKETING ADVERSE DRUG EXPERIENCE INSPECTIONAL PROGRAM CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO.
Ken Falci, Ph.D.,Director, OSAS Center for Food Safety and Applied Nutrition (CFSAN) FDA, College Park, MD.
SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.
Adverse Events and Unanticipated Problems Presented by: Karen Jeans, PhD, CCRN, CIP COACH Program Analyst.
Patient Safety and Medical Devices Sonia Swayze, RN, MA, C and Suzanne Rich, RN, MA, CT.
1 Disclosures © HIPAA Pros 2002 All rights reserved.
1 Nuts and Bolts of Safety Reporting The Role of the CRO Dr. Noa Lowenton Spier Pharma-Clinical S.A.G.
PSO Participation for the Leadership Team (Presenter) (Date) 1 **For internal use by Center for Patient Safety PSO Participants. May not otherwise be photocopied,
1 MÉNARD, MARTIN, AVOCATS THE RIGHT TO SAFE CARE LEGAL ISSUES By: Mtre. Jean-Pierre Ménard, Ad. E.
Informal Claims And Inferred Claims.
Federal Laws CHAPTER 3. DRUG REGULATION Timeline highlights –Food Drug & Cosmetic (FDC) Act –Durham Humphrey Amendment –Poison Prevention Packaging Act.
Center for Food Safety and Applied Nutrition (CFSAN) Golriz Khadem And Ryan Leitz.
1 Non-Sedating Antihistamines Rx-to-OTC Switch NDAC & PADAC Joint Meeting May 11, 2001 François Nader, MD Senior Vice-President Medical & Regulatory Affairs,
CWA DISTRICT 7 CONFERENCE VANCOUVER WA. MAY 2011 SAFETY.
A Guide for Barber Professionals Liability and Risk Reduction Associated Hair Professionals ©2012.
Implementation of the Proposed Canada Consumer Product Safety Act (Bill C-6) Mandatory Reporting Health Canada ICPHSO 2009, Toronto.
PSO Education for [agency/organization]’s PSES Workgroup (Presenter) (Date) 1 **For internal use by Center for Patient Safety PSO Participants. May not.
PSO Overview for Executives (Presenter) (Date) Center for Patient Safety Toolkit for PSO Participation, Section 4.
Patient's Responsibilities. You should provide a complete and accurate medical history. You should provide a complete and accurate medical history. You.
Hazard Communication Presentation Presented by: Western Assurance Corp Desert Utility & Paving, LLC and Century Club Construction, LLC Design © 2005, 2012.
C HAPTER 34 Code Blue Health Sciences Edition 4. Confidentiality of sensitive information is an important issue in healthcare. Breaches of confidentiality.
PSO Overview for (name of organization’s) PSES Workgroup (Presenter) (Date) 1 **For internal use by Center for Patient Safety PSO Participants. May not.
PSL 503: Policy, Economics & Environment Unit 7 Legislative Environment: Impact on Patient Safety Reporting.
© 2007 Dechert LLP Pharmacovigilance Reporting and Analysis: Product Liability Concerns Diane P. Sullivan.
Enforcement Litigation and Compliance Washington, DC December 9- 10, 2015 Food: Industry Self Regulation Hal Hodes, Attorney, National Advertising Division.
Office of Research Oversight 1 Office of Research and Development Local Accountability Meeting January 2009.
FDA1 Overview of Postmarketing Safety Surveillance in FDA (For Drugs and Biologics) Min Chen, M.S., R.Ph. Min Chen, M.S., R.Ph. Associate Director Division.
1 Advance Directives For Behavioral Health Care Materials used with Permission From the National Resource Center on Psychiatric Advance Directives NJ Division.
European Patients’ Academy on Therapeutic Innovation Introduction to pharmacovigilance Monitoring the safety of medicines.
NASA JSC David T. Loyd Safety and Test Operations Division
FDA Notifications and Medwatch Form Requirements Adverse Event Reporting for OTC Drugs and Dietary Supplements.
Complaint Handling Medical Device Reporting May 19, 2016 Rita Harden, Director Customer Relations & Regulatory Reporting.
Patient Safety Organization Overview (Presenter) (Date) 1 **For internal use by Center for Patient Safety PSO Participants. May not otherwise be photocopied,
Storage, Labeling, Controlled Medications Guidance Training CFR § (b)(2)(3)(d)(e) F431.
KEVIN BEDAL LISA CARLIN MATT CARROLL ERIN NICHOLS Product Safety & Failure Analysis.
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP

Remote Monitoring of Adverse Events
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Patient Medical Records
HIPAA Pros - Disclosures
Remote Monitoring of Adverse Events
SERIOUS ADVERSE EVENTS REPORTING
PSO Overview for (name of organization’s) PSES Workgroup
PSO Overview for Executives
PSO Overview for (name of organization’s) PSES Workgroup
PSO Overview for Executives
Presentation transcript:

Council for Responsible Nutrition Supplyside West, October 19, 2006 The Case for Mandatory Reporting of Adverse Events for Dietary Supplements Steve Mister President & CEO Council for Responsible Nutrition

2 Council for Responsible Nutrition Supplyside West, October 19, What S / H.R Does: Requires that manufacturers provide FDA with all reports they receive of serious adverse events associated with their dietary supplements within 15 days of receipt. Dietary supplement labeling must include an address or telephone number through which a report of a serious adverse event may be received. Manufacturers must keep records of all adverse event reports they receive for 6 years. Pre-empts states from enacting their own systems

3 Council for Responsible Nutrition Supplyside West, October 19, What is an Adverse Event? A negative health-related experience Associated with an FDA regulated product May or may not be caused or connected with the use of the product

4 Council for Responsible Nutrition Supplyside West, October 19, A Serious Adverse Event is... … an event that results in: –Death, –A life threatening experience, –Inpatient hospitalization or prolonging of an existing hospitalization, –A persistent or significant disability or incapacity, or –A congenital anomaly or birth defect, –An incident that requires medical or surgical intervention to prevent one of the above.

5 Council for Responsible Nutrition Supplyside West, October 19, This legislation is not about incentivizing consumers to generate more AERs — it’s about requiring manufacturers to inform FDA of the serious AERs that they already receive.

6 Council for Responsible Nutrition Supplyside West, October 19, Consumers Already Report Adverse Events to FDA FDA Receives AE reports now through: CAERS – CFSAN Adverse Event Reporting System, Medwatch, and FDA District Coordinators as reported (on a voluntary basis) by –Doctors, pharmacists and other healthcare professionals –Emergency Rooms –Poison Control Centers –Manufacturers –Consumers

7 Council for Responsible Nutrition Supplyside West, October 19, The Value of AERs FDA considers AERs “a monitoring tool to identify potential public health issues that may be associated with the use of a particular product already in the marketplace.” AERs serve as early warning signals of possible problems, not as conclusions (see ephedra). AERs can help to identify concerns with ingredient safety, manufacturing issues, contamination (of either raw ingredients or finished products), tamperings, and bio-terrorism.

8 Council for Responsible Nutrition Supplyside West, October 19, The Value of AERs (cont.) Review of AERs by a single entity can suggest trends or potential commonalities across brands or companies, identify a common supplier, and define the scope of a problem. Treated as “safety reports,” AERs are protected under the FD&CA and cannot be used in litigation as an admission of causality. FDA emphatically states that AERs are useful for developing hypotheses, they are not meant to prove them.

9 Council for Responsible Nutrition Supplyside West, October 19, No one – except possibly the opponents of this bill – has suggested that AERs can, or should, prove causality.

10 Council for Responsible Nutrition Supplyside West, October 19, Why AERs are Needed While many companies report voluntarily, one company making an ephedra supplement allegedly had thousands of AERs that it didn’t report. Many consumers perceive that dietary supplements are not safe and FDA doesn’t know enough about our products. We have a credibility problem as long as a manufacturer can legally receive a serious AER, put in in a locked file cabinet, and pretend it never happened.

11 Council for Responsible Nutrition Supplyside West, October 19, Mandatory AERs are What A Responsible Industry Does It’s the right thing to — responsible manufacturers put their consumers first. It will improve the public health by giving FDA early signals with respect to DS. It will improve public perceptions of DS as a regulated industry. States are increasingly interested in AERs, even if Congress wasn’t. Along with GMPs (coming soon?), AE reporting will help level the playing field; identify issues of quality among fringe players; and provide “bookends” on product quality.

12 Council for Responsible Nutrition Supplyside West, October 19, Status of the Legislation

Council for Responsible Nutrition Supplyside West, October 19, 2006 Ten Myths & the Facts About AERs

14 Council for Responsible Nutrition Supplyside West, October 19, Myth #1: The bill should only require reporting of adverse events caused by a dietary supplement. Facts: Submission of the report does not involve a judgment call by the mfr. Gives FDA an earlier signal; may prevent harm had the mfr. waited for proof of causality. Act of filing of a report can’t be used to lend credence to the report — legislation protects mfrs from inference of causation. AERs widely-recognized as merely serving as possible warning signal, as with other FDA regulated products. No admission of a causal connection.

15 Council for Responsible Nutrition Supplyside West, October 19, Myth #2: The law should just require a Medwatch phone number on the label instead. Facts: Consumers would call FDA Medwatch directly. Would likely encourage over-reporting. Even non-serious AEs would be reported directly to FDA. FDA would know before the mfr does — mfr may not even know that report has been filed. Mfrs would lose the ability to make quick corrections to address concerns. Mfrs want to interface with their consumers and know the most about their products.

16 Council for Responsible Nutrition Supplyside West, October 19, Myth #3: Plaintiffs’ attorneys can use AERs to develop class action law suits. Facts: AERs are subject to nondisclosure of private information provisions of the Privacy Act and HIPPA. –All personal or identifying information is redacted. –Two courts of appeals have specifically denied plaintiffs’ attorneys access to this information with respect to drug AERs. Along with the AER, a manufacturer may submit a statement denying that the report constitutes an admission. Legislation directs FDA to avoid duplicate reports of the same event. AERs are considered a “safety report” under section 756 of the FD&C Act.

17 Council for Responsible Nutrition Supplyside West, October 19, Liability Protection “... such report or information shall not be construed to reflect necessarily a conclusion by the entity or the Secretary [of HHS] that the report or information constitutes an admission that the product involved malfunctioned, caused or contributed to an adverse experience, or otherwise caused or contributed to death, serious injury or serious illness. Such an entity need not admit, and may deny, that the report or information submitted by the entity constitutes an admission that the product involved malfunctioned, caused or contributed to an adverse experience, or otherwise caused or contributed to death, serious injury or serious illness.” FD&C Act §756 (21 U.S.C. §379v ) FD&C Act §756 (21 U.S.C. §379v )

18 Council for Responsible Nutrition Supplyside West, October 19, Myth #4: Mandatory reporting will provide a roadmap to plaintiffs’ attorneys of the “next big case.” Facts: Mfrs may submit additional information that negates the AE or exculpates the product. Any exculpatory information becomes part of the report and must be provided when the report is disseminated. Attorneys already have access to Medwatch reports today. That already gives them signals of AE reported directly to FDA. Why should mfr-reported cases be any different that those reported directly to FDA?

19 Council for Responsible Nutrition Supplyside West, October 19, Myth #5: Consumers Will Overwhelm FDA With Adverse Event Reports. Facts: Consumers can already report AEs to FDA via Medwatch now. Many mfrs already report serious AEs to FDA now. Many OTCs are already subject to mandatory AERs. We’ve been telling the world about the wide margins of safety of our products for years. Are we telling the truth? So why isn’t FDA being overwhelmed now? The opposition’s math is misguided. There is no “flashing neon sign” for consumers in the legislation.

20 Council for Responsible Nutrition Supplyside West, October 19, Myth #6: AERS Will Prevent Mfrs from Getting Product Liability Insurance. Facts: Underwriters already ask about claims histories and any AERs the mfr is aware of. Insurance carriers can review AERs that FDA already receives. Mandatory reporting will give insurance carriers more confidence they are getting the whole story. Mandatory reporting creates more transparency in the insurance marketplace and more accurate information on which to base premiums.

21 Council for Responsible Nutrition Supplyside West, October 19, Myth #7: Even if the bill is limited to “serious” AERs, mfrs will need to report everything to be safe. Facts: The legislation defines “serious AERs” using existing criteria for drugs. The definition provides concrete parameters for what is “serious.” Why take on more responsibility that you need to?

22 Council for Responsible Nutrition Supplyside West, October 19, Myth #8: We don’t need AERs if FDA would just promulgate GMPs. Facts: Rx drugs have both GMPs and mandatory AERs. We don’t know when/if FDA will release the GMPs. If the ingredient is unsafe, no amount of GMPs will solve that problem. GMPs and AERs provide bookends of safety: –GMPs help assure quality products under quality conditions. –AERs provide post-market surveillance in case an unsafe product slips through.

23 Council for Responsible Nutrition Supplyside West, October 19, Myth #9: Mandatory AE reporting will drive up the cost of DS. Facts: Many OTCs (including ibuprofen, naproxen, and hydrocortisone) have been living under this model for years. Many mfrs routinely maintain a call center or get AEs now; how are they handled now. Legislation permits contracts with call center vendors. How many serious adverse event reports do you really receive in a year?

24 Council for Responsible Nutrition Supplyside West, October 19, Myth #10: AER Legislation Will Deny Consumers Access to Dietary Supplements. Facts: Nothing in the legislation limits access to dietary supplements. Mandatory AERs will demonstrate to FDA the safety of supplements. If anything, AERs will lead to more-informed consumers, able to make smarter supplement choices.

Council for Responsible Nutrition Supplyside West, October 19, 2006

26 26

Council for Responsible Nutrition Supplyside West, October 19, 2006 Questions? Contact me at: (202)